United Therapeutics announced that its Phase III TETON-2 clinical trial for patients with interstitial lung disease (ILD) has met its primary endpoint.

Data shows that after 52 weeks of treatment, patients using Tyvaso (treprostinil) inhalation solution demonstrated statistically significant improvements in absolute forced vital capacity (FVC). This randomized, double-blind, placebo-controlled study aimed to evaluate the efficacy and safety of Tyvaso in improving lung function in ILD patients. Absolute FVC, as a core indicator for measuring the degree of lung function recovery, yielded positive results that validate Tyvaso's clinical value in slowing disease progression. The study results further strengthen Tyvaso's position in the treatment of pulmonary arterial hypertension and ILD, providing key data support for expanding its indications. The company stated that it will communicate with global regulatory agencies based on these study results to promote Tyvaso's clinical application in more regions.